Leaps by Bayer

From all of us at Leaps by Bayer, thank you for making this year a success. 🌟 Through collaboration, innovation, and shared achievements, we’ve made meaningful progress together. The support of our community inspires us to keep striving for a healthier and more sustainable future. Here’s to reaching even greater heights in the year ahead! 🚀

Ready to leap into 2025? We are! But first, let’s take a moment to reflect on the strides we’ve made together in 2024. This year, we proudly made over 30 new and follow-on investments, bringing us to 65+ companies and over $2 billion invested since 2015. Our portfolio companies achieved remarkable progress this year. Just to name a few highlights: In #health, milestones in clinical trials were reached by Recursion, NextPoint Therapeutics, Inc., Sudo Biosciences, Mozart Therapeutics, Inc., Affini-T Therapeutics, ReCode Therapeutics, Indapta Therapeutics, and BlueRock Therapeutics - paving the way for innovative treatments and breakthroughs. On the agricultural side, partnerships between Bayer | Crop Science and Grão Direto and Pairwise advanced #sustainable solutions for tomorrow’s challenges, keeping us firmly focused on the #futureoffood and farming. We are also deeply honored to have the work of our portfolio recognized by notable institutions such as TIME, BloombergNEF, Endpoints News, Fast Company, and HLTH USA. This acknowledgment inspires us to continue driving bold innovations for a healthier and more sustainable world. As 2024 draws to a close, we are filled with gratitude for our partners, collaborators, and visionaries who share this journey with us. Here’s to an even brighter 2025! 💙

The answers inside us all 🧬 Juergen Eckhardt, Head of Leaps, in his latest Forbes article discusses 5 of the most exciting breakthroughs this year. From stem cell treatments that restore vision to the pioneers using RNA to push forward gene editing’s frontier. To read the full article, click the link in the comments.

Congratulations to the Sound Agriculture team on this incredible milestone! Seeing your commitment to advancing #sustainable #agriculture and supporting growers with innovative solutions is inspiring. We're honored to be part of this journey and excited for what’s ahead. 🌱

How do we account for the #impact potential within our portfolio? Quick answer: #WALYs. WALYs allow for comparison of life satisfaction between affected and non-affected people. To calculate WALYs, a large number of people are asked to report on their own experienced quality of life and their circumstances. The severity of diseases or environmental impacts are then measured in terms of people's/patients' life satisfaction on a scale from 0 (lowest wellbeing) to 1 (highest wellbeing). Innovations in agriculture impact society on multiple levels. For each of the latter named KPIs, we have developed a data-backed methodology to translate the benefits into WALYs. Read on in our impact report: https://lnkd.in/ex4QjMuV

There is a __ in our diet!  🍔 We don't eat enough dietary fiber anymore, because modern overprocessed food often is low in fiber but high in sugar. The team at one.bio is here to change that and we are more than excited to be able to support them. ➡️ Swipe to learn more.

A forgotten star of human health. ⭐ Juergen Eckhardt, Head of Leaps, discusses in his latest Forbes article the importance of dietary fiber for our health as well as the innovative startups developing technologies, to add it back into our food. To read the full article, click the link in the comments.

🎉 One more announcement in 2024: Leaps by Bayer announced its participation in one.bio's Series A funding round. 🌱 One.bio closes a gap in our portfolio and in our health by reintroducing active plant fibers into our diet. Lack of fiber intake and consequently malnutrition of the modern diet is at root of the public health crisis of today - modern inflammatory disease. 💡 The result has been an imposing spike in chronic inflammatory, cardiovascular and neurodegenerative diseases, autoimmunity, and cancers. Read more here: http://bit.ly/49GC5hG

How do we account for the #impact potential within our portfolio? Quick answer: #WALYs. WALYs allow for comparison of life satisfaction between affected and non-affected people. To calculate WALYs, a considerable number of individuals were asked to report on their own experienced quality of life and their circumstances. The severity of diseases or environmental impacts were then measured in terms of people's/patients' life satisfaction on a scale from 0 (lowest wellbeing) to 1 (highest wellbeing). Read on in our impact report: https://lnkd.in/ex4QjMuV

Transforming the way #autoimmunediseases are treated. 🚀 We are excited to welcome Nuvig Therapeutics Inc. to the Leaps portfolio. Millions of patients live with the challenges of autoimmune conditions, and current treatments often come with significant compromises, such as suppressed immune function. Nuvig Therapeutics is leading the way in developing next-generation immune modulators that address the root causes of autoimmune dysregulation – without sacrificing immune health. Their core technology harnesses an endogenous regulatory mechanism that resolves autoimmune dysregulation. Find out more: https://lnkd.in/gxhqHG_v